Open Access iconOpen Access

ARTICLE

ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma

FEI LIU1, JIAZHANG WEI2, JIAO LAN1, YONGLI WANG2, JIANXIANG YE3, CHENG Su1, MINGZHENG MO1, FENGZHU TANG2, BING LI2, MIN LI2, WEIMING DENG2, LINSONG YE2, Wenlin HUANG2, JINGJIN WENG2, WEI JIAO1,*, SHENHONG QU2,*

1 Research Center of Medical Sciences, The People’s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, 530021, China
2 Department of Otolaryngology & Head and Neck, The People’s Hospital of Guangxi Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, 530021, China
3 Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, 530021, China

* Corresponding Authors: WEI JIAO. Email: email; SHENHONG QU. Email: email

(This article belongs to this Special Issue: Tissue Engineering, Cellular Therapy and Biotechnologies in Plastic Surgery)

BIOCELL 2022, 46(12), 2659-2669. https://doi.org/10.32604/biocell.2022.022886

Abstract

Our previous studies suggested a potential interaction between the POK erythroid myeloid ontogenic factor ZBTB7A and glucose transporter 1 (GLUT1) in nasopharyngeal carcinoma (NPC). This study was designed to confirm the interaction and further evaluate the precise mechanism by which ZBTB7A and GLUT1 regulate NPC development. The binding sites between ZBTB7A and the promoter of GLUT1 were predicted by bioinformatics. Gene expression was measured by quantitative real-time polymerase chain reaction (qPCR), western blotting, and immunohistochemistry. The activities of key glycolysis enzymes, including hexokinase (HK), pyruvate kinase (PK), lactate dehydrogenase (LDH), and lactate, were detected using specific enzyme-linked immunosorbent assay kits. The connection between ZBTB7A and GLUT1 was analyzed by dual-luciferase reporter assay and chromatin immunoprecipitation–qPCR. The vitality, proliferation, and tumorigenicity of the cells expressing different levels of ZBTB7A were tested by adding the glycolysis inhibitor 2-deoxy-D-glucose (2-DG), followed by MTT, colorimetric focus forming, and xenograft assays, respectively. Our results showed that high expression of GLUT1 was associated with late-stage NPC. After constructing stably transfected cells with lentiviruses, ZBTB7A was effectively knocked down in 5-8F cells (RNAi-5-8F) and overexpressed in 6-10B cells (ZBTB7A-6-10B). The up- or downregulation of GLUT1 secondary to ZBTB7A changes was also limited. The vitality and proliferation of the cells expressing low ZBTB7A were notably blocked by 2-DG. The cells expressing high ZBTB7A were not very sensitive to 2-DG. The growth of RNAi-5-8F xenografts was strongly suppressed by 2-DG. The activities of HK, PK, and LDH were suppressed by 2-DG in the cells expressing low ZBTB7A. RNAi-5-8F cells had the lowest 2-DG-induced lactate production. ZBTB7A directly suppressed the promoter region of GLUT1 to regulate GLUT1 expression. Thus, ZBTB7A controls the 2-DG-induced inhibition of glycolysis by affecting GLUT1.

Keywords


Cite This Article

LIU, F., WEI, J., LAN, J., WANG, Y., YE, J. et al. (2022). ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma. BIOCELL, 46(12), 2659–2669. https://doi.org/10.32604/biocell.2022.022886



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1176

    View

  • 649

    Download

  • 1

    Like

Share Link